Estudo comparativo entre estibogluconato de sódio BP 88® e antimoniato de meglumina no tratamento da leishmaniose cutânea II. Toxicidade bioquímica e cardíaca

Saldanha, Ana Cristina R.; Romero, Gustavo; Guerra, Conceição; Merchán-Hamann, Edgar; Macêdo, Vanize

doi:10.1590/s0037-86822000000400009

Cited by 27 publications

(18 citation statements)

References 9 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to different authors, the success rate varies from 26% to 100% of patients treated after a first period of antimony administration [4][5][6][7][8] . In another study conducted in Cuiabá, State Major Article of Mato Grosso, Brazil, the failure rate was 47%, that is, no healing or recrudescence of skin lesions was found during the three month followup after the first treatment regimen 9 .…”

Section: Introductionmentioning

confidence: 99%

The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil

Diniz

Costa

Escalda

2012

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Governador Valadares is an endemic area of American tegumentary leishmaniasis (ATL). The detection rate was 15.36 per 100,000 habitants from to 2006(Miranda, 2008. This study aimed to analyze the effects of age on the frequency of adverse reactions caused by antimony in the treatment of ATL in the City of Governador Valadares, State of Minas Gerais, Brazil, during 2009. Methods: Data were collected from the forms of the Information System for Notifiable Diseases, and from charts, questionnaires, and home visits to patients. Results: The study included 40 patients, 26 (65%) of whom were males. Individuals over the age of 50 had a 66% higher rate of adverse effects than subjects who were 50 years old or less (CI 95%, 1.14-2.41). The average age of individuals who reported some type of adverse effect was 44.11 years (SD = 20.14), while the average age of the group that did not report any adverse effect was of 25.46 years (SD = 18.37; p < 0.01). Clinical healing was 67.5%, and 10% of patients discontinued the treatment. Conclusions: In the treatment of ATL, the age of patients should be considered, because most adverse reactions occur in individuals over 50 years of age. For this reason, the drug should be used with restriction in these cases.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil

Diniz

Costa

Escalda

2012

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…Other therapeutic options of proven efficacy are amphotericin B, pentamidine and aminosidine 12,13,17 . All of these drugs are administered by the parenteral route, present several side and toxic effects and must be used for several weeks 5,18 . Oral medications such as imidazole and triazole derivatives and allopurinol, among others, have been used, with var iable responses 1,3 .…”

mentioning

confidence: 99%

Efficacy of azithromycin in the treatment of cutaneous leishmaniasis

Prata

Silva‐Vergara

Costa³

et al. 2003

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

The present open pilot study was conducted to assess the efficacy of azithromycin for the treatment of patients with cutaneous leishmaniasis in Araçuaí and Varzelândia, MG. Twenty-four patients with less of six months of disease evolution were treated after clinical examination, Montenegro test and a biopsy. The treatment schemes consisted of oral doses of 500 mg per day for 3, 5 and 10 days and of 1000 mg for two days. A clinical control was performed monthly and treatment cycles were repeated when necessary until full reepithelialization of the lesions. On the occasion of the final evaluation, 20 patients had completed the study and 17 of them (85%) were cured. The time to obtain a cure was 60 days ifor 6 (30%) patients, 90 days for 7 (35%), and 120 for 4 (20%). The three patients with treatment failure received a pentavalent antimonial for 20 days. No adverse reactions to the medication were observed and a 14 month follow-up did not show recurrence in any patient. These results suggest that azithromycin can be a good therapeutic option for the treatment of cutaneous leishmaniasis caused by Leishmania Viannia brasiliensis. Key words: Cutaneous leishmaniasis. Azithromycin. Leishmania Viannia brasiliensis.Resumo O presente estudo piloto aberto avaliou a eficácia da Azitromicina em pacientes com leishmaniose cutânea, em Araçuaí e Varzelândia, MG. Foram tratados 24 pacientes após exame clínico, teste de Montenegro, e biópsia, e que tivessem menos de seis meses de evolução da doença. Os esquemas de tratamento empregaram doses, pela via oral, de 500 mg por dia durante 3,5 e 10 dias e de 1000 mg durante dois dias. Mensalmente foi realizado controle clínico e quando necessário, repetidos ciclos do medicamento, até reepitelização completa das lesões. Na avaliação final 20 pacientes terminaram o estudo, dos quais 17 (85%) foram curados. O tempo de cura foi de 60 dias em 6 (30%) pacientes, de 90 dias em 7 (35%) e de 120 dias em 4 (20%). Os três pacientes que tiveram falha terapêutica receberam antimonial pentavalente durante 20 dias. Não foram observadas reações adversas ao medicamento e o seguimento até 14 meses pós-tratamento não mostrou recidiva em nenhum dos pacientes. Estes resultados sugerem que a Azitromicina pode ser uma boa opção terapêutica para o tratamento de leishmaniose cutânea causada por Leishmania Viannia brasiliensis.

show abstract

“…One child developed marked QTc alteration (500 ms) which passed from view on the fourth week of treatment. Meanwhile, the data for adult population is much higher, 22% [8,9,11] and only one publication gives a lower value, 8% [15].…”

Section: Discussionmentioning

confidence: 94%

“…More rarely bradycardia and extrasystoles were observed [8][9][10]. The total of ECGs changes amount to 53.8% of patients receiving antimony medication [11].…”

Section: Introductionmentioning

confidence: 99%

Antimony Containing Drug and ECG Abnormalities in Children with Visceral Leishmaniasis

Zanoni

Brustoloni

Melnikov

et al. 2009

Biol Trace Elem Res

View full text Add to dashboard Cite

The objective of the paper was to evaluate the influence of antimony (5+) on electrocardiographic changes in children with visceral leishmaniasis. The study was based on weekly ECGs analysis of 87 children treated, from April 2001 to May 2006, with antimoniate N-methyl glucamine. Eligible subjects included children from 6 months to 12 years of age with weight of 6-34 kg. Forty-five children (52%) were males and forty-two (48%) were females. The cardiac response to antimony was significantly milder compared to the adult populations, so the usage of meglumine antimoniate is safer. Thus, during treatment sinus rhythm was maintained without ectopic beats. No changes were observed in the P wave and in PR interval. The QRS complex remained unaltered during the treatment, the amplitude being increased. The Sokolow's indexes exceeded normal values in one child on the first week and in eight children on the fourth. The prolongation of QTc occurred in ten patients. The T wave flattening was observed in seven children on the first week. In total, ECG abnormalities were detected in 34.4% of treatment courses, while in adults they were reported in 53.8%. Antimony therapy needs ECG monitoring of the cardiac function in order to prevent complications.

show abstract

Estudo comparativo entre estibogluconato de sódio BP 88® e antimoniato de meglumina no tratamento da leishmaniose cutânea II. Toxicidade bioquímica e cardíaca

Cited by 27 publications

References 9 publications

The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil

The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil

Efficacy of azithromycin in the treatment of cutaneous leishmaniasis

Antimony Containing Drug and ECG Abnormalities in Children with Visceral Leishmaniasis

Contact Info

Product

Resources

About